RxDoctor Payments Data

Randal Brown, MD

Family Medicine · Fort Worth, TXNPI 1831167956

Payments from drug & device makers

$9,701in general payments, 2019–2025

Across 610 payments — averaging $15.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$964
  • Lilly USA, LLC$908
  • AstraZeneca$878
  • GSK$540
  • Astellas Pharma US Inc$438
  • plus $5K from 37 others

What the payments were for

  • Food & beverage$9,54598%
  • Education$1562%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$9,701 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$386,430
Medicare patients
530
Services billed
6,250

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin249$243,151
OzempicSemaglutide181$237,716
TrulicityDulaglutide121$169,088
EliquisApixaban85$104,252
Trelegy ElliptaFluticasone/Umeclidin/Vilanter72$62,144
JanuviaSitagliptin Phosphate64$59,702
FarxigaDapagliflozin Propanediol40$42,798
MounjaroTirzepatide33$37,364
MyrbetriqMirabegron33$29,898
Tresiba Flextouch U-100Insulin Degludec29$26,401
ProliaDenosumab15$25,502
XareltoRivaroxaban30$25,427
JanumetSitagliptin Phos/Metformin Hcl18$21,890
LinzessLinaclotide27$20,946
Breztri AerosphereBudesonide/Glycopyr/Formoterol21$19,078

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$438$243,151249 claims
Novo NordiskOzempic$1,387$237,716181 claims
Lilly USA, LLCTrulicity, Mounjaro$908$206,452154 claims
PfizerEliquis, Premarin$317$112,141101 claims
MerckJanuvia, Janumet, Belsomra$207$89,03697 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix$540$75,408105 claims
AstraZenecaFarxiga, Breztri Aerosphere$878$61,87661 claims
Astellas Pharma US IncMyrbetriq$438$29,89833 claims
AmgenProlia$342$25,50215 claims
Johnson & JohnsonXarelto$381$25,42730 claims
AbbVieLinzess$964$20,94627 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Fort Worth

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →